UCL Innovation and Enterprise



How to respond when the grand vision becomes a cold reality

New ventures are started for many reasons, with one of the most common routes beginning with someone doing a job they like in a big company and thinking they want to do it for themselves, but where do they go from there, asks Timothy Barnes, Director of UCL Enterprise Operations and UCL Advances.

Publication date:

Business letters: October 20

YOU say that turning university science projects into big companies is mostly impossible (“Imperial needs to pick more winners”, last week). Yet the acquisition of Spirogen by Astra Zeneca for $440m (£272m) last week shows that substantial returns to investors are possible from university research.
Read: The Sunday Times

Publication date:

UCL and Photobiotics announce partnership to tackle gastric cancer

UCL, Photobiotics pursue new approach to gastric cancer
A new collaboration between University College London (UCL) and PhotoBiotics, a targeted oncology company spun out from Imperial College London in the UK, is looking to develop a multifunctional agent for use in both the diagnosis and treatment of gastric cancer.
Read: PharmaTimes

Publication date: